Table 3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Figshare2025-09-17 更新2026-04-28 收录

数据链接：

https://figshare.com/articles/dataset/Table_3_from_Phase_2_Study_of_Zilovertamab_Vedotin_in_Participants_with_Metastatic_Solid_Tumors/30146469 数据链接链接失效反馈

官方服务：

资源简介：

Summary of AEs.

创建时间：

2025-09-17

腔道粒子支架植入剂量计算数据集

放疗剂量

实体瘤治疗

本数据集是针对BrachyTPS软件的剂量计算模块对非实体肿瘤的剂量计算结果的开发和验证。非实体肿瘤不同于有具体形态的实体肿瘤，在进行近距离放疗时需要使用粒子支架，所以剂量计算程序于实体瘤有一定的差别。针对腔道粒子支架植入剂量计算，我们使用两种放射性粒子125I粒子、复合粒子分别使用BrachyTPS软件进行剂量计算以及蒙特卡洛开源软件Gate8 .2进行剂量计算，争取对该软件的剂量计算模块进行全

国家基础学科公共科学数据中心120

S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers

实体瘤治疗

药物疗效评估

The purpose of the study is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor mali

NIAID Data Ecosystem50

Augmenting CAR T Cell Function with LIGHT. Augmenting CAR T Cell Function with LIGHT

CAR-NKT细胞疗法

实体瘤治疗

Chimeric antigen receptor (CAR) T cell therapy has shown remarkable clinical success in the treatment of B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphoma (NHL), and multiple myeloma (

NIAID Data Ecosystem40

Factors associated with increased risk of prescribing errors.

处方错误

临床药物安全性

Factors associated with increased risk of prescribing errors.

Figshare2021-01-12 更新50

Subject Disposition at Week 24 (Treated Analysis Set).

临床药物安全性

不良事件监测

*Adverse events leading to study drug discontinuation: Immediate Switch: emergent to EFV/FTC/TDF—anxiety; insomnia; night sweatsDelayed Switch: emergent to ABC/3TC + EFV (baseline to Wk12)—depressionD

Figshare2015-12-03 更新40

Table 3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

资源简介：

相关数据集